Eosinophilic pneumonia overview: Difference between revisions
m (Changes made per Mahshid's request) |
No edit summary |
||
| Line 7: | Line 7: | ||
==Historical Perspective== | ==Historical Perspective== | ||
In 1944, Hamman described a group of four otherwise healthy patients who developed progressive lung disease, known as '''''[[Hamman-Rich syndrome]]. I'''n 1989, Acute eosinophilic pneumonia was first described by Badesch and colleagues. In 1969, Carrington was the first to describe chronic eosinophilic pneumonia and known as [[Carrington syndrome|'''Carrington syndrome''']].'' | |||
==Classification== | ==Classification== | ||
Eosinophilic lung diseases may be classified according to the cause into; pneumonias of unknown cause such as [[Chronic eosinophilic pneumonia|idiopathic chronic eosinophilic pneumonia]] and i[[Idiopathic acute eosinophilic pneumonia|diopathic acute eosinophilic pneumonia]], pneumonias of known cause such as [[allergic bronchopulmonary aspergillosis]] and eosinophilic pneumonias of [[parasitic]] origin, and eosinophilic airways diseases such as [[Hypereosinophilic syndrome|hypereosinophilic]] asthma and idiopathic hypereosinophilic constrictive [[bronchiolitis]]. | |||
==Pathophysiology== | ==Pathophysiology== | ||
==Causes== | ==Causes== | ||
Causes of eosinophilic lung diseases are acute eosinophilic pneumonia, chrnoic eosinophilic pneumonia, [[tropical pulmonary eosinophilia]], [[Granulomatosis with polyangiitis|eosinophilic granulomatosis with polyangitis]], [[allergic bronchopulmonary aspergillosis]], and [[medications]] such as [[Non-steroidal anti-inflammatory drug|nonsteroidal anti-inflammatory drugs]], [[Anticonvulsants]], [[Antidepressants]], [[Angiotensin converting enzyme inhibitors]], and [[Beta blockers]]. | |||
==Differentiating from other Diseases== | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
The [[prevalence]] of idiopathic chronic eosinophilic pneumonia (ICEP) remains unknown. The [[incidence]] of chronic eosinophilic pneumonia in an Icelandic registry was 0.23 cases/100,000 population per year between 1990 and 2004. ICEP has been reported to contribute to 0 to 2500 per 100,000 of cases included in different registries of [[Interstitial lung disease|interstitial lung diseases]]. There is no racial predilection to ICEP. Women are more commonly affected by ICEP than men. ICEP typically affects patients in their 30s or 40s. | |||
==Risk Factors== | ==Risk Factors== | ||
Risk factors for eosinophilic pneumonia vary according to the type; acute pneumonia is related to the recent initiation of tobacco smoking. One third to one-half of the chronic pneumonia patients have a history of [[asthma]]. | |||
== Screening == | |||
There is no specific screening for eosinophilic pneumonia. | |||
== Natural History, Complications and Prognosis== | |||
If left untreated, patients with eosinophilic pneumonia may progress to develop dyspnea, pleural effusion, and respiratory failure. Common complications of eosinophilic pneumonia include [[Respiratory failure|respiratory failure,]] [[relapse]], and [[Adverse effect (medicine)|adverse effects]] of [[Steroid|steroids]]. Prognosis is generally excellent, and only a couple of lethal cases have been reported. | |||
==Diagnostic Criteria== | |||
== History and symptoms == | |||
== Physical Examination == | |||
== Laboratory Findings == | |||
== Other Diagnostic Studies == | |||
== Medical Therapy == | |||
== Surgery == | |||
== Prevention == | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 05:08, 2 March 2018
|
Eosinophilic pneumonia Microchapters |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Eosinophilic pneumonia overview On the Web |
|
American Roentgen Ray Society Images of Eosinophilic pneumonia overview |
|
Risk calculators and risk factors for Eosinophilic pneumonia overview |
Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Priyamvada Singh, M.D. [2]
Overview
Eosinophilic pneumonia (EP) is a disease in which a certain type of white blood cell called an eosinophil accumulates in the lung. These cells cause disruption of the normal air spaces (alveoli) where oxygen is extracted from the atmosphere. Several different kinds of eosinophilic pneumonia exist and can occur in any age group. The most common symptoms include cough, fever, difficulty breathing, and sweating at night. EP is diagnosed by a combination of characteristic symptoms, findings on a physical examination by a health provider, and the results of blood tests and x-rays. Prognosis is excellent once most EP is recognized and treatment with corticosteroids is begun.
Historical Perspective
In 1944, Hamman described a group of four otherwise healthy patients who developed progressive lung disease, known as Hamman-Rich syndrome. In 1989, Acute eosinophilic pneumonia was first described by Badesch and colleagues. In 1969, Carrington was the first to describe chronic eosinophilic pneumonia and known as Carrington syndrome.
Classification
Eosinophilic lung diseases may be classified according to the cause into; pneumonias of unknown cause such as idiopathic chronic eosinophilic pneumonia and idiopathic acute eosinophilic pneumonia, pneumonias of known cause such as allergic bronchopulmonary aspergillosis and eosinophilic pneumonias of parasitic origin, and eosinophilic airways diseases such as hypereosinophilic asthma and idiopathic hypereosinophilic constrictive bronchiolitis.
Pathophysiology
Causes
Causes of eosinophilic lung diseases are acute eosinophilic pneumonia, chrnoic eosinophilic pneumonia, tropical pulmonary eosinophilia, eosinophilic granulomatosis with polyangitis, allergic bronchopulmonary aspergillosis, and medications such as nonsteroidal anti-inflammatory drugs, Anticonvulsants, Antidepressants, Angiotensin converting enzyme inhibitors, and Beta blockers.
Differentiating from other Diseases
Epidemiology and Demographics
The prevalence of idiopathic chronic eosinophilic pneumonia (ICEP) remains unknown. The incidence of chronic eosinophilic pneumonia in an Icelandic registry was 0.23 cases/100,000 population per year between 1990 and 2004. ICEP has been reported to contribute to 0 to 2500 per 100,000 of cases included in different registries of interstitial lung diseases. There is no racial predilection to ICEP. Women are more commonly affected by ICEP than men. ICEP typically affects patients in their 30s or 40s.
Risk Factors
Risk factors for eosinophilic pneumonia vary according to the type; acute pneumonia is related to the recent initiation of tobacco smoking. One third to one-half of the chronic pneumonia patients have a history of asthma.
Screening
There is no specific screening for eosinophilic pneumonia.
Natural History, Complications and Prognosis
If left untreated, patients with eosinophilic pneumonia may progress to develop dyspnea, pleural effusion, and respiratory failure. Common complications of eosinophilic pneumonia include respiratory failure, relapse, and adverse effects of steroids. Prognosis is generally excellent, and only a couple of lethal cases have been reported.